Skip to content
DraconiticResearch
Search Sources API
184,584 studies31 sourcesUpdated 39 min ago
Peer-reviewedCC BYCancers

Treatment-Free Interval as a Prognostic Factor for Survival Outcomes in Patients with Advanced or Recurrent Endometrial Cancer Treated with Pembrolizumab Plus Lenvatinib: A Multi-Institutional Real-World Cohort Study

  • Chih-Wen Su1
  • Shao-Jing Wang2
  • Yu-Hsiang Shih2
  • Ting-Fang Lu2
  • Yen-Fu Chen2
  • Chun-Ting Fan2
  • Shih-Tien Hsu2
  • Chih-Ku Liu2
  • Lou Sun2
  • Sheau-Feng Hwang2
  • Chien-Hsing Lu1
  • Chia-Che Chang1
  1. 1Doctoral Program in Translational Medicine, Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung 402202, Taiwan;
  2. 2Department of Gynecology and Obstetrics, Taichung Veterans General Hospital, Taichung 407219, Taiwan; (S.-J.W.);
Read full textPDFCite

Related

  1. Pembrolizumab plus lenvatinib in the treatment of unresectable cutaneous angiosarcoma: a study protocol of multicentre, open-label phase II study (NCCH2213, PLAS)
    Dai Ogata, Eiji Nakano, Naoya Yamazaki +10
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textOncologyCrossref
  2. Lenvatinib starting doses below 20 mg versus 20 mg with pembrolizumab in advanced or recurrent endometrial cancer: a systematic review and meta-analysis of comparative observational evidence
    Yu Wu, Juncheng Wei, Chuyue Chang +4
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsCrossrefEurope PMCPMC
  3. Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
    Jordi Remon, Paolo Bironzo, Nicolas Girard +17
    Lancet OncologyPeer-reviewedLicence not statedFull text14 citedNeurologyHAL
  4. Recurrent TFE3-Rearranged Renal Cell Carcinoma Responding to Pembrolizumab Plus Lenvatinib After Postoperative Pembrolizumab: A Case Report.
    Masashi Fujimoto, Tomoyasu Sano, Yuta Sano +7
    IJU case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy
    J.W. Lee, P.E. Oberstein, J.D. Goldberg +9
    ESMO Gastrointestinal OncologyPeer-reviewedCC BY-NC-NDFull textOncologyDOAJEurope PMCEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{su2026treatmentfree,
  title = {{Treatment-Free Interval as a Prognostic Factor for Survival Outcomes in Patients with Advanced or Recurrent Endometrial Cancer Treated with Pembrolizumab Plus Lenvatinib: A Multi-Institutional Real-World Cohort Study}},
  author = {Chih-Wen Su and Shao-Jing Wang and Yu-Hsiang Shih and Ting-Fang Lu and Yen-Fu Chen and Chun-Ting Fan and Shih-Tien Hsu and Chih-Ku Liu and Lou Sun and Sheau-Feng Hwang and Chien-Hsing Lu and Chia-Che Chang},
  journal = {Cancers},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13664632},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Treatment-Free Interval as a Prognostic Factor for Survival Outcomes in Patients with Advanced or Recurrent Endometrial Cancer Treated with Pembrolizumab Plus Lenvatinib: A Multi-Institutional Real-World Cohort Study
AU  - Chih-Wen Su
AU  - Shao-Jing Wang
AU  - Yu-Hsiang Shih
AU  - Ting-Fang Lu
AU  - Yen-Fu Chen
AU  - Chun-Ting Fan
AU  - Shih-Tien Hsu
AU  - Chih-Ku Liu
AU  - Lou Sun
AU  - Sheau-Feng Hwang
AU  - Chien-Hsing Lu
AU  - Chia-Che Chang
PY  - 2026
DA  - 2026/09/22
JO  - Cancers
UR  - https://europepmc.org/article/PMC/PMC13664632
SN  - 2072-6694
ER  -